In 2017, the diagnosed prevalent population of Mydriasis in the United States was 3,580,350. In the United States the Cataract Surgeries performed in the age-specific cases (70–79) in 2017 were 1,390,000.
The market size of Mydriasis in the seven major markets was USD 104.52 million in 2017.
Rising Geriatric population and cost-effectiveness of the Current Standard of Care are the key factors expected to drive the Mydriasis market forward in the coming years.
The key companies in the Mydriasis market include Ocuphire Pharma, Théa Laboratories, Omeros Corporation and others.
For more detailed information on Mydriasis market, visit:
https://www.delveinsight.com/report-store/mydriasis-market